CClinicalTrials.gg
Sign In
Enrolling by invitationNCT03876847SCAD-INSPIREUpdated Apr 14, 2026

Genetics of Spontaneous Coronary Artery Dissection (SCAD-INSPIRE Genetics)

An observational study in Spontaneous Coronary Artery Dissection, sponsored by Intermountain Health Care, Inc.. Enrolling by invitation. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Intermountain Health Care, Inc. · Observational

Study type
Observational
Model
Family-based
Time perspective
Cross-sectional
Enrollment
100
Sex
All
01

Study summary

Spontaneous coronary artery dissection (SCAD) is a rare cause of coronary ischemia and infarction where a tear in blood vessel wall either restricts the flow of blood or the blood becomes trapped in between the layers of the vessel causing the vessel to impinge on the lumen and causing an obstruction or restriction of blood flow. The ultimate goal of this proposal is to further understand the risk factors leading to SCAD with a focus on familial and genetic causes of SCAD.

Read the detailed description

For this study, we will ascertain clinical data and biological samples from a cohort of SCAD patients identified using retrospective review of medical records and prospective surveillance of Intermountain patients that undergo coronary angiography. The SCAD diagnosis will be based on independent review of clinical presentation, cardiac imaging, and angiography findings by two cardiologists and a third cardiologist in case of disagreement. It is anticipated that we hope to recruit 100 SCAD patients.

Enrollment of these subjects will be done under the INSPIRE registry. The subjects will be asked to sign a consent, provide biological samples, and complete questionnaires related to SCAD as part of the INSPIRE registry.

The SCAD cases will be matched to records in the Intermountain Genealogy Registry (IGR) to allow for the identification of possible high-risk SCAD families. Risk of first and second degree relatives will also be assessed. The obtained blood samples will be processed, stored and genotyped.

02

Conditions studied

  • Spontaneous Coronary Artery Dissection
03

In context

Lead sponsor

Intermountain Health Care, Inc. is the lead sponsor of 118 studies on the registry; 15 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 3 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will be Intermountain Healthcare patients. The case subjects will be SCAD patients and the control population for the genetics will be Intermountain angiography patients without SCAD.

Inclusion criteria

SCAD Cases

  1. Subjects of all ages, gender, or race
  2. Subjects had coronary angiography.
  3. Subjects had suspected SCAD as based on clinical report.

Controls

  1. INSPIRE subject that had coronary angiography at Intermountain Healthcare for stable angina.
  2. Subjects had no or mild atherosclerotic heart disease at time of angiography.
  3. Age at last visit as recorded in the Intermountain EDW at least 50 years or older.
  4. Not screened as possibly having a SCAD or coronary artery dissection diagnosis.

Exclusion criteria

Exclusion Criteria:

SCAD Cases

  1. Independent review of cardiac imaging and clinical presentation by three cardiologists determine the coronary angiography was not a result of SCAD.
  2. Imaging from time of coronary angiography of poor quality as to not allow for proper determination of SCAD.
  3. Inability to determine criteria as outlined above.
  4. Subjects that have had a heart transplant.
  5. Subjects that have had a bone marrow transplant.
  6. Inability or refusal of the patient and/or the patient's legally acceptable representative to provide informed consent or blood sample for any reason.
  7. Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the trial.

Controls

  1. Subjects that have a heart transplant.
  2. Subjects that have a bone marrow transplant.

  3. Subjects with any of the following diagnosis at anytime

    1. Heart failure
    2. Heart valve disease
    3. Thoracic aortic aneurysm and dissection
    4. Ehlers-Danlos syndrome
    5. Shprintzen-Goldberg syndrome
    6. Marfan syndrome
    7. Loeys-Dietz aortic aneurysm syndrome
    8. Arterial tortuosity syndrome
05

Study design

Observational model
Family-based
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Spontaneous Coronary Artery Disection

    The spontaneous coronary artery disection (SCAD) diagnosis will be based on independent review of clinical presentation, cardiac imaging, and angiography findings by three cardiologists. The determination will be evidence of linear luminal defect (intimal flap) detection, luminal narrowing or occlusion confirmed to be a dissection on further imaging, or by clinical judgment classifying it as definite SCAD.

  • Control

    A set of controls will be used for genetic analysis. These controls will pulled from subjects in the INSPIRE registry that had coronary angiography at Intermountain Medical Center for stable angina and meet inclusion/exclusion criteria.

06

What researchers measure

Primary outcomes

  1. Genetic variants

    To determine genetic variants among spontaneous coronary artery dissection (SCAD) patients, we will do genotyping including target sequencing and whole exome/genome sequencing on samples provided by SCAD patients. The primary focus of this sequencing will be to determine rates of variants in genes that cause cardiac-related connective tissue disorders.

    Time frame: at enrollment

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03876847
Lead sponsor
Intermountain Health Care, Inc.
Responsible party
Sponsor
First posted
Mar 15, 2019
Start date
Oct 17, 2016
Primary completion
Dec 31, 2036 (estimated)
Completion
Dec 31, 2036 (estimated)
Last update
Apr 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Coronary Artery Dissection, Spontaneous

Other studies from this sponsor

Intermountain Health Care, Inc.

Start the discussion